According to a recently published report by Research Nester on “Chickenpox (Varicella) Vaccine Market: Global Demand Analysis & Opportunity Outlook 2027” delivers detailed overview of the chickenpox (varicella) vaccine market in terms of market segmentation by product type, by product application and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Chickenpox (Varicella) vaccine market is segmented by product type, product application and region. Based on product type, the market is segmented into monovalent vaccine and combination vaccine. On the basis of product application, the market is segmented into chickenpox, herpes zoster and post herpetic neuralgia. The chickenpox (varicella) vaccine market is anticipated to record a CAGR of around 7.8% during the forecast period i.e. 2019-2027. The segments are anticipated to have significant growth attributing to the fact that medicines which are given separately, are given together in one shot preventing three diseases together. The global varicella vaccine industry is concentrated with around 72.50% of the market share in production is grasped by the top 5 manufacturers. Amongst which, Merck holds 30.40%, GSK holds 10.04%, and Shanghai Institute holds 11.60% and other manufacturers hold 47.96% of the market share of the varicella vaccine market.

Asia- Pacific is expected to grow at a high rate owing to rising health concerns and continuous developments in the healthcare sector. North- America is expected to grow significantly on the back of government funding on healthcare facilities. Latin America and Middle- East are expected to grow significantly attributing to increase in consumption of life saving drugs.

Prevalence of Chickenpox

Not every person is vaccinated against chickenpox which increases chances of its occurrence. With increasing prevalence of chickenpox in people the need to get vaccinated increases which is expected to boost the growth of the chickenpox (varicella) vaccine market.

Rising government funding on healthcare facilities

Due to growing prevalence of chickenpox in people (both children and adults), the government is increasing its funding on healthcare and providing healthcare facilities such as availability of vaccine at subsidized rates, free or subsidized consultancy services etc. which is expected to boost the growth of the chickenpox (varicella) vaccine market.  

However, high cost of vaccine is expected to act as a key restraint towards the growth of chickenpox (varicella) vaccine market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the chickenpox (varicella) vaccine market which includes company profiling of Biken, Green Cross, Merck & Co. and GlaxoSmithKline, Changsheng Bio Technology Corporation Ltd., Changchun BCHT Biotechnology Corporation Ltd., Shanghai Institute, Medlmmune, Protein Sciences Corporation and Emergent Biosolutions. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the chickenpox (varicella) vaccine market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.